Neuroblastoma - Epidemiology Forecast to 2027

DelveInsight’s "Neuroblastoma - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Neuroblastoma epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Neuroblastoma EpidemiologyThe epidemiology section covers the historical, current as well as forecasted epidemiology for Neuroblastoma in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Neuroblastoma outlook. It also includes the explanation of changing trends of epidemiology outlining the Neuroblastoma scenario.

Neuroblastoma Epidemiology SegmentationThe epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Neuroblastoma thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope• The report covers detailed overview of Neuroblastoma explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan• The Neuroblastoma Report assesses the disease risk and burden and highlights the unmet needs• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Parent Industry

Related Industries

Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immunotherapies are in clinical development across a range of solid tumor types. The most advanced in development are checkpoint inhibitors. These checkpoint inhibitors have dramatically altered the natural history...

United States Biopsy Market will cross US$ 17 Billion by the year 2024 owing to the rising prevalence of cancer in the region. According to the World Health Organization, cancer cases are expected to surge 57% worldwide in the next 20 years. Biopsies are most often done to look for cancer; a biopsy is a sample of tissue...

About Lumpectomy A lumpectomy is a form of breast-conserving and preservation surgery used for the removal of breast tumor or some surrounding tissues. It is also known as a partial mastectomy because a part of breast tissue is removed in this procedure, whereas in mastectomy, the full breast is removed to avoid chances...

Glioma clinical trials report from VPA Research provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions. The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical...

Glioma clinical trials report from VPA Research provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions. The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical...

Glioma clinical trials report from VPA Research provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions. The report focuses on drugs and therapies being evaluated for Glioma treatment in active clinical...